Thyroid transcription factor 1 immunohistochemistry as an intraoperative diagnostic tool at frozen section for distinction between primary and secondary lung tumors

被引:0
|
作者
Butcher, David N. [1 ]
Goldstraw, Peter
Ladas, George
Dusmet, Michael E.
Sheppard, Mary N.
Nicholson, Andrew G.
机构
[1] Royal Brompton Hosp, Dept Histopathol, London SW3 6NP, England
[2] Royal Brompton Hosp, Dept Thorac Surg, London SW3 6NP, England
关键词
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Context.-Intraoperative distinction between primary and metastatic carcinomas in the lung at frozen section remains problematic. Objective.-To assess the value and practicality of immunohistochemistry for thyroid transcription factor 1 at the time of intraoperative frozen section. Design.-Thirty-three patients presented with either a solitary pulmonary mass or 2 pulmonary masses and a history of carcinoma in a different organ. In addition to routine frozen section for assessment of tumor type, we looked for expression of thyroid transcription factor 1, using the EnVision system with abridged methodology. Results.-Ten cases were positive for thyroid transcription factor 1, which was confirmed on subsequent paraffin sections. Nine of these were confirmed as primary pulmonary adenocarcinomas, but I case proved to be a rare false-positive metastatic colonic carcinoma. Twenty-three cases were negative on frozen section and reported as favoring metastatic disease. In all cases, additional immunohistochemical data increased diagnostic confidence, but particularly in cases of positive primary pulmonary tumors and in cases with disease metastatic from sites other than the large bowel. The average time in addition to that of the basic frozen section was 24 minutes per test with a cost of 32 pound (US$57). Conclusions.-Frozen section immunohistochemistry for thyroid transcription factor 1 shows specificity and sensitivity similar to those seen for formalin-fixed tissues and is feasible within the time frame of a thoracotomy. Diagnostic confidence is increased, especially with positive primary pulmonary tumors. However, its practice should be properly planned within an operative procedure as liberal usage will likely have significant staff and cost implications.
引用
收藏
页码:582 / 587
页数:6
相关论文
共 44 条
  • [31] The prognostic value of cytokeratin 7, 19, thyroid transcription factor-1 and CD117 expression in lung neuroendocrine tumors of various grades
    Gurevich, L.
    Korsakova, N.
    Voronkova, I.
    Kazantseva, I.
    Ashevskaya, V.
    Titov, A.
    Kogoniya, L.
    Byakhova, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [32] RELATIONSHIP BETWEEN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION, THYROID TRANSCRIPTION FACTOR 1 (TTF-1), AND PROGNOSIS OF PATIENTS WITH NON-SMALL-CELL LUNG CANCER
    Mai, Zhitao
    Jiang, Mingming
    Zhang, Ling
    Di, Qingguo
    Du, Junfeng
    Zhang, Xin
    Chi, Yumin
    Zhou, Lirong
    Lv, Jing
    Shi, Jian
    Kang, Xiaoling
    Li, Jianhui
    Kong, Xiangjun
    Li, Min
    Song, Zhan
    Zhang, Ying
    Han, Guangchao
    Sun, Baohua
    ACTA MEDICA MEDITERRANEA, 2019, 35 (06): : 3323 - 3329
  • [33] Diagnostic role of immunostaining for thyroid transcription factor 1 (TTF1) and paired box 8 (PAX8) in distinguishing pulmonary metastases of mesonephric and mesonephric-like adenocarcinomas from primary lung adenocarcinoma
    Kim, H.
    Ji, N.
    Kim, H.
    VIRCHOWS ARCHIV, 2024, 485 : S89 - S90
  • [34] A high-density tissue microarray(TMA) and immunohistochemistry(IHC) study of thyroid transcription Factor-1(TTY-1) expression in non-small-cell lung cancer(NSCLC)
    Tan, DF
    Li, Q
    Deeb, G
    Slocum, HK
    Ramnath, N
    Loewen, G
    Wiseman, S
    Brooks, JJ
    MODERN PATHOLOGY, 2003, 16 (01) : 314A - 314A
  • [35] Diagnostic Value of Immunostaining for Thyroid Transcription Factor 1 (TTF1) and Paired Box 8 (PAX8) in Distinguishing Pulmonary Metastases of Mesonephric and Mesonephric-like Adenocarcinomas from Primary Lung Adenocarcinomas
    Ji, Nayoon
    Lee, Yurimi
    Lee, Sang Hwa
    Kim, Hyun-Soo
    ANTICANCER RESEARCH, 2024, 44 (05) : 2159 - 2170
  • [36] Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens
    Chhieng, DC
    Cangiarella, JF
    Zakowski, MF
    Goswami, S
    Cohen, JM
    Yee, HT
    CANCER CYTOPATHOLOGY, 2001, 93 (05): : 330 - 336
  • [37] Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: A high-throughput tissue microarray and immunohistochemistry study
    Tan, DF
    Li, Q
    Deeb, G
    Ramnath, N
    Slocum, HK
    Brooks, J
    Cheney, R
    Wiseman, S
    Anderson, T
    Loewen, G
    HUMAN PATHOLOGY, 2003, 34 (06) : 597 - 604
  • [38] A high-density tissue microarray(TMA) and immunohistochemistry(IHC) study of thyroid transcription factor-1 (TTF-1) expression in non-small-cell lung cancer(NSCLC)
    Tan, DF
    Li, Q
    Deeb, G
    Slocum, HK
    Ramnath, N
    Loewen, G
    Wiseman, S
    Brooks, JJ
    LABORATORY INVESTIGATION, 2003, 83 (01) : 314A - 314A
  • [39] Effect of Primary Hypothyroidism on Fetal Mouse Lung Surfactant Protein A, B and C, and Thyroid Transcription Factor-1 Protein and Gene Expression.† 1456
    Mohammed Ansari
    Uday P. Devaskar
    Stacy J. Hicks
    Daphne E. deMello
    Pediatric Research, 1997, 41 (Suppl 4) : 245 - 245
  • [40] p40 & thyroid transcription factor-1 immunohistochemistry: A useful panel to characterize non-small cell lung carcinoma-not otherwise specified (NSCLC-NOS) category
    Walia, Ritika
    Jain, Deepali
    Madan, Karan
    Sharma, Mehar C.
    Mathur, Sandeep R.
    Mohan, Anant
    Iyer, Venkateswaran K.
    Kumar, Lalit
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2017, 146 : 41 - 47